A bogus pharmacy, which pretended to be based in Canada, has been held responsible for the death of a Canadian resident who bought drugs via the Internet. The British Columbia Coroners Office announced that Marcia Bergeron, from Quadra Island, Canada, had died from ingesting pills containing dangerous level of heavy metals, including strontium and uranium.
The coroner's report found that over 100 tablets were discovered in Mrs Bergeron's home, none of them labeled and some without packaging. Three drugs were identified, for which the victim was not found to have any prescriptions. These were: zolpidem, a sedative developed by France's Sanofi-Aventis under the brand name Ambien, that is available on prescription in the USA but not licensed in Canada; Pfizer's Xanax (alprazolam), a prescribable anti-anxiety remedy; and acetaminophen, which is an over-the-counter drug in Canada. The US Food and Drug Administration issued a warning in February about the first two of the drugs which, the agency warned, contained haloperidol, a powerful anti-psychotic drug (Marketletter February 26).
Margaret MacDiarmid, president of the BC Medical Association, told the Vancouver Sun newspaper that "the idea of taking any of these powerful medications without having a diagnosis and a treatment plan is really very frightening."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze